Lexicon Pharmaceuticals | LXRX - Ebit

Stock Price
1.61
Daily Change
-0.04 -2.42%
Monthly
0.63%
Yearly
135.04%
Q2 Forecast
1.60

Lexicon Pharmaceuticals reported $-14.78M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Abbott USD 1.85B 684M Mar/2026
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Illumina USD 239M 17M Mar/2026
Insmed USD -249.71M 11.64M Dec/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
J&J USD 6.62B 1.51B Mar/2026
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
MacroGenics USD -12.1M 32.26M Dec/2025
MannKind USD -69.24M 28.19M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Moderna USD -1.39B 531M Mar/2026
Novartis USD 4.18B 118M Mar/2026
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Thermo Fisher Scientific USD 1.91B 389M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
United Therapeutics USD -14.6M 403.9M Dec/2025
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024